Beximco PharmaceuticalsBXMPY 91 EV-to-FCF is 84.67 as of Jul. 02, 2026, which is 276% above its 10-year median of 22.51. GuruFocus rates BXMPY with a GF Score™ of 91/100. The stock has 4 warning signs investors should review. Among 560 Drug Manufacturers companies, Beximco Pharmaceuticals ranks worse than 80.89% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Beximco Pharmaceuticals's Enterprise Value is $952.81 Mil.
Beximco Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $11.25 Mil. Therefore, Beximco Pharmaceuticals's EV-to-FCF for today is 84.67.
The historical rank and industry rank for Beximco Pharmaceuticals's EV-to-FCF or its related term are showing as below:
BXMPY'
s EV-to-FCF Range Over the Past 10 Years
Min: -863.74 Med: 22.51 Max: 8182.81
Current: 72.47
During the past 13 years, the highest EV-to-FCF of Beximco Pharmaceuticals was 8182.81. The lowest was -863.74. And the median was 22.51.
BXMPY's EV-to-FCF is ranked worse than 80.89% of 560
companies
in the Drug Manufacturers industry
Industry Median: 20.52
vs BXMPY: 72.47
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beximco Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Beximco Pharmaceuticals's share price for today is $0.00.
Beximco Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's EV-to-FCF falls into.
Beximco Pharmaceuticals's current Enterprise Value is $952.81 Mil.
Beximco Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals (BXMPY) has a EV-to-FCF of 84.67 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Beximco Pharmaceuticals and its competitors. This is 276% above median its historical median of 22.51. According to the industry distribution chart, Beximco Pharmaceuticals ranks #453 out of 560 companies in the Drug Manufacturers industry, placing it in the top 80.9%.
Is Beximco Pharmaceuticals' EV-to-FCF too high?
Beximco Pharmaceuticals' current EV-to-FCF of 84.67 is 276% above median its 10-year median of 22.51. The Drug Manufacturers industry median EV-to-FCF is 20.52. Beximco Pharmaceuticals' value of 84.67 is 312.6% above this industry median. Based on the distribution chart, Beximco Pharmaceuticals ranks #453 out of 560 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beximco Pharmaceuticals has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #453 out of 560 companies for EV-to-FCF. This places Beximco Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 20.52. Beximco Pharmaceuticals' value of 84.67 is 312.6% above this benchmark. While the company's 10-year median is 22.51 vs. the industry median of 20.52, Beximco Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.52, based on 560 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current EV-to-FCF of 84.67 is 312.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current EV-to-FCF is 84.67, which is 276% above median its own 10-year median of 22.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current EV-to-FCF of 84.67. The current EV-to-FCF is 84.67, which is 276% above median its 10-year median of 22.51 and 312.6% above the Drug Manufacturers industry median of 20.52. Beximco Pharmaceuticals' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current EV-to-FCF is 84.67 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 